AXSM Stock Summary and Trading Ideas (Axsome Therapeutics | NASDAQ:AXSM)

Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.

Axsome Therapeutics trades on the NASDAQ stock market under the symbol AXSM.

As of September 11, 2026, AXSM stock price climbed to $226.50 with 297,013 million shares trading.

AXSM has a beta of 0.35, meaning it tends to be less sensitive to market movements. AXSM has a correlation of 0.02 to the broad based SPY ETF.

AXSM has a market cap of $11.86 billion. This is considered a Large Cap stock.

Last quarter Axsome Therapeutics reported $218 million in Revenue and -$.99 earnings per share. This fell short of revenue expectation by $-4 million and missed earnings estimates by -$.12.

In the last 3 years, AXSM traded as high as $260.19 and as low as $55.02.

The top ETF exchange traded funds that AXSM belongs to (by Net Assets): VTI, VB, VBK, VXF, FBT.

AXSM has outperformed the market in the last year with a price return of +82.5% while the SPY ETF gained +18.6%. However, in the short term, AXSM had mixed performance relative to the market. It has underperformed in the last 3 months, returning -8.1% vs +5.8% return in SPY. But in the last 2 weeks, AXSM shares have fared better than the market returning +9.8% compared to SPY -0.7%.

AXSM support price is $206.55 and resistance is $215.68 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that AXSM shares will trade within this expected range on the day.